Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Daily Feed
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Energy
    • Robotics
    • Bio & Healthcare
  • Toggle search form

[Disclosure] Celltrion (068270) Decides to Cancel 9.11 Million Treasury Shares Valued at Approx. KRW 1.72T for Shareholder Value Enhancement

Posted on March 24, 2026July 14, 2026 By K-STOCK Editor No Comments on [Disclosure] Celltrion (068270) Decides to Cancel 9.11 Million Treasury Shares Valued at Approx. KRW 1.72T for Shareholder Value Enhancement

Fact Source: Financial Supervisory Service DART / 2026-03-24

Disclosure Type: Decision on Share Retirement (Cancellation of Treasury Shares)

💡 3-Second Summary

To stabilize its stock price and boost shareholder value, Celltrion has resolved to retire and permanently cancel 9.11 million of its previously acquired treasury shares (estimated at approximately KRW 1.715 trillion in value) on April 1, 2026.

📊 1. [Summary of Key Disclosure Content and Major Figures]

  • Type and Number of Shares to be Retired: 9,110,000 Common Shares
  • Estimated Total Retirement Amount: KRW 1,715,413,000,000 (Approx. KRW 1.72T)
    • Calculated by multiplying the number of shares by the closing price of KRW 188,300 on March 23, 2026 (the day before the board resolution).
  • Method of Acquisition: Retirement of previously acquired treasury shares (no additional market purchase is required for this action).
  • Scheduled Retirement Date: April 1, 2026 (Subject to potential change during consultations with relevant regulatory bodies).
  • Date of Board Resolution: March 24, 2026 (All 5 outside directors attended).
  • Total Outstanding Common Shares (Before Retirement): 231,048,261 Shares

[Additional Details]

  • Pursuant to Article 343, Paragraph 1 of the Commercial Act, this retirement will reduce the total number of issued shares but will not decrease the company’s stated capital.
  • Out of the 9,110,000 shares to be retired, 7,154,087 shares were acquired within the distributable profit limit (average acquisition cost per share: KRW 167,860), and 1,955,913 shares were acquired for specific purposes (average acquisition cost per share: KRW 189,666).

📈 2. [Expert Perspective: What This Disclosure Means for Investors]

This retirement of treasury shares is a highly positive event that directly enhances the company’s fundamental per-share metrics. While purchasing treasury shares can sometimes leave overhang risks (since the company might resell them in the market later), a formal “retirement” permanently deletes these shares, ensuring they will never return to the circulating supply.

Consequently, key financial indicators such as Earnings Per Share (EPS) and Book Value Per Share (BPS) for existing shareholders are highly likely to increase. The scale of this retirement represents approximately 3.94% of the total issued common shares (approx. 231 million shares), making it a massive capital management move valued at over KRW 1.7 trillion, which could exert a positive psychological impact on the market.

However, investors should note that since this process reduces only the total number of outstanding shares without altering the legal capital stock, there will be no reduction in the capital figure on the balance sheet. The actual retirement date is currently scheduled for April 1, 2026, but minor adjustments may occur depending on coordination with administrative agencies.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion has delivered a tangible, massive action by completely wiping out KRW 1.72 trillion worth of treasury shares, rather than just offering verbal promises of shareholder returns. Released alongside its official Corporate Value-up Plan, this retirement decision acts as a strong signal from management to support the stock price. Reducing the total share count immediately upgrades the intrinsic value of each remaining share—excellent news for long-term investors. Instead of chasing short-term price fluctuations, investors could use this opportunity to recalculate the post-retirement valuation of Celltrion.

📢 Disclaimer and Source Information

Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s electronic disclosure system (DART).

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Celltrion (068270) Announces Corporate Value-up Plan Targeting 30% CAGR and 40% Shareholder Return Rate for ’25~’27
Next Post: [Disclosure] Celltrion (068270) Approves Financials with KRW 4.16T Revenue and Confirms KRW 750 Cash Dividend per Common Share at AGM

Related Posts

[Disclosure] Samsung Biologics (207940) Designated as Short-Selling Overheated Stock… Short-Selling Banned on January 23 for 1 Day Disclosures
[Disclosure] Alteogen(196170) Issued Preliminary ‘Investment Warning’ Notice and Designated as ‘Investment Caution’ Stock on August 26 Following Over 200% Surge in a Year Disclosures
[Disclosure] Celltrion (068270) Decides to Repurchase KRW 100B Worth of Treasury Shares to Stabilize Stock Price and Enhance Shareholder Value Disclosures
[Disclosure] Samsung Biologics(207940) Reports Q1 2024 Operating Profit of KRW 221.3B, Up 15.41% YoY Disclosures
[Disclosure] Alteogen (196170) Reports FY2025 Operating Profit of KRW 106.9B, Surging 320.8% YoY Disclosures
[Disclosure] Samsung Electronics (005930) Revises Q2 Metrics Upward, Confirming 74.07T KRW Revenue and 10.44T KRW Operating Profit Semiconductors

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Celltrion (068270) Submits Application to Modify Phase 3 Clinical Trial Plan for ‘CT-P44’ (Darzalex Biosimilar) in EuropeJuly 14, 2026
  • [Disclosure] Hanmi Semiconductor (042700) Reports Q2 2026 Operating Profit of KRW 130.3B… A Explosive 1,441.4% QoQ SurgeJuly 14, 2026
  • [Disclosure] SK Square (402340) Discloses Subsidiary SK Hynix’s Successful ADR Listing on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] SK Hynix (000660) Completes Listing of ADRs (American Depositary Receipts) on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] Samsung Electronics (005930) to Dispose of KRW 322.8B Worth of Treasury Shares for Executive BonusesJuly 13, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme